Skip to main navigation
Vaccitech
  • Home
  • Our Team
    • About
  • Technology
  • Pipeline
  • Partnerships
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financials
    • Investor Resources
  • Careers
  • Contact
Select Page

News Releases

  • Subscribe
  • RSS Feeds
  • Contact IR
  • Presentations
  • News Releases
  • Events
  • News Releases
  • Events
Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
Jan 18, 2022
OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
Jan 13, 2022
Live webcast will be at 8:30 a.m. EST on January 25 OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a

Vaccitech Limited

The Schrödinger Building
Heatley Road
The Oxford Science Park
Oxford
OX4 4GE

T: +44 (0)1865 818808

  • Home
  • About
  • Sitemap
  • Privacy Policy
  • Privacy Notice
  • Careers
  • Contact

Vaccitech is a T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer

  • Twitter
  • LinkedIn
© Vaccitech 2022 All rights reserved.